专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL177922D0 MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF 未知
公开(公告)号：IL177922D0
公开(公告)日：2006-12-31
申请号：IL17792206
申请日：2006-09-06
申请人： MERCK PATENT GMBH , NICHOLAS RONALD GLOVER , MATTHEW BAKER , FRANCIS J CARR , KOEN HELLENDOORN , JEANNICK CIZEAU , GLEN CHRISTOPHER MACDONALD , JOYCELYN ENTWISTLE , DENIS GEORGES BOSC
IPC分类号： A61K38/00 , A61K38/16 , A61K39/395 , A61K47/48 , A61P35/00 , C07K7/08 , C07K14/415 , C07K16/30 , C07K16/44 , C07K19/00 , C12N20100101 , C12N15/11 , C12N15/13 , C12N15/29 , C12N15/62
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

2. 发明授权

US08716234B2 Cytotoxins comprising modified bouganin toxin for the treatment of cancer 有权
标题翻译：细胞毒素包含改良的bouganin毒素用于治疗癌症
公开(公告)号：US08716234B2
公开(公告)日：2014-05-06
申请号：US12784820
申请日：2010-05-21
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译：本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。

3. 发明授权

US07524502B2 Modified anti-TNF alpha antibody 失效
标题翻译：修饰的抗TNFα抗体
公开(公告)号：US07524502B2
公开(公告)日：2009-04-28
申请号：US10495146
申请日：2002-11-11
申请人： Koen Hellendoorn , Matthew Baker , Francis J. Carr
发明人： Koen Hellendoorn , Matthew Baker , Francis J. Carr
IPC分类号： A61K39/395
CPC分类号： C07K7/08 , C07K16/241 , C07K2317/24 , C07K2317/56
摘要： The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.
摘要翻译：本发明涉及对人肿瘤坏死因子α（TNFα）具有反应性的抗体的修饰，以产生当在体内使用时与任何未修饰的亲本抗体基本上不具有免疫原性或较低免疫原性的抗TNFα抗体。本发明还涉及包含通过氨基酸改变修饰的亲本抗体的V区的T细胞表位的肽分子，以便减少或消除所述T细胞表位。

4. 发明授权

US07135282B1 Viral particles with exogenous internal epitopes 失效
标题翻译：具有外源内部表位的病毒颗粒
公开(公告)号：US07135282B1
公开(公告)日：2006-11-14
申请号：US10110511
申请日：2000-10-13
申请人： Koen Hellendoorn , Tim Jones
发明人： Koen Hellendoorn , Tim Jones
IPC分类号： C12N7/00 , A61K36/00
CPC分类号： C12N7/00 , A61K39/12 , A61K39/292 , A61K2039/5256 , C12N2730/10134 , C12N2760/10034 , C12N2760/18834 , C12N2770/18034 , Y02A50/412 , Y10S530/806 , Y10S530/826
摘要： The present invention relates to the expression of peptides on viral particles, and more particularly to the expression of peptides on the interior or the viral capsid. Methods are described for modifying viruses so that exogenous epitopes are expressed on the interior of the viral capsid. Viruses that can be modified include (+) stranded RNA viruses, especially plant (+) stranded RNA viruses such as the cowpea mosaic virus. Internal expression is especially useful for the expression of hydrophobic epitopes. The modified viral particles also find use as vaccines and as such are capable of eliciting an immune response.
摘要翻译：本发明涉及肽在病毒颗粒上的表达，更具体地涉及肽在内部或病毒衣壳上的表达。描述了用于修饰病毒的方法，使得外源表位在病毒衣壳的内部表达。可以修饰的病毒包括（+）链RNA病毒，特别是植物（+）链RNA病毒如cow豆花叶病毒。内表达对疏水性表位的表达特别有用。修饰的病毒颗粒也可用作疫苗，因此能够引发免疫应答。

5. 发明授权

US06979448B1 Chimaeric plant viruses with mucin peptides 失效
标题翻译：具有粘蛋白肽的嵌合植物病毒
公开(公告)号：US06979448B1
公开(公告)日：2005-12-27
申请号：US10070566
申请日：2000-09-11
申请人： Mary Bendig , Tim Jones , Koen Hellendoorn
发明人： Mary Bendig , Tim Jones , Koen Hellendoorn
IPC分类号： A61K39/00 , C07K14/08 , C07K14/47 , C12N7/01 , C12N15/12 , C12N15/40 , C12N15/82 , A61K39/12 , A61K48/00
CPC分类号： C07K14/005 , A61K39/0011 , A61K2039/5256 , A61K2039/543 , A61K2039/57 , A61K2039/6075 , C07K14/4727 , C12N15/8203 , C12N15/8257 , C12N2770/18022
摘要： Mucin peptide epitopes are inserted into the coat protein of a plant virus (e.g., a comovirus such as CPMV) having a beta-barrel structure at an immunogenically effective site, such as in a loop connecting beta sheets or at/near the C-terminus. The resulting chimaeric virus particles are extremely immunogenic, giving better results than KLH conjugation and not requiring the addition of exogenous adjuvant. They are effective at mucosal surfaces, particularly when administered intranasally.
摘要翻译：将粘蛋白肽表位插入到在免疫原性有效位点处具有β-桶结构的植物病毒（例如，联合病毒如CPMV）的外壳蛋白中，例如连接β片或C末端附近的环。所得到的嵌合体病毒颗粒是非常免疫原性的，比KLH缀合更好的结果，并且不需要添加外源性佐剂。它们在粘膜表面有效，特别是在鼻内施用时。

6. 发明申请

US20050238642A1 Modified bouganin proteins, cytotoxins and methods and uses thereof 有权
标题翻译：改良的bouganin蛋白，细胞毒素及其方法和用途
公开(公告)号：US20050238642A1
公开(公告)日：2005-10-27
申请号：US11084080
申请日：2005-03-18
申请人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
发明人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
IPC分类号： A61K38/00 , A61K38/16 , A61K39/395 , A61K47/48 , A61P35/00 , C07K7/08 , C07K14/415 , C07K16/30 , C07K16/44 , C07K19/00 , C12N15/11 , C12N15/13 , C12N15/29 , C12N15/62
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译：本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。

7. 发明授权

US07879338B2 Vectors and methods for immunization against norovirus using transgenic plants 有权
标题翻译：使用转基因植物免疫诺如病毒的载体和方法
公开(公告)号：US07879338B2
公开(公告)日：2011-02-01
申请号：US10895791
申请日：2004-07-21
申请人： William D.O. Hamilton , Koen Hellendoorn , Timothy D. Jones , Dwayne D. Kirk , Hugh S. Mason , Xiuren Zhang , Charles J. Arntzen
发明人： William D.O. Hamilton , Koen Hellendoorn , Timothy D. Jones , Dwayne D. Kirk , Hugh S. Mason , Xiuren Zhang , Charles J. Arntzen
IPC分类号： C12N15/40 , C12N5/04 , C12N1/21 , A61K39/125 , A01H5/00 , A01H5/08 , A01H5/10
CPC分类号： C12N15/8258 , A61K2039/5258 , A61K2039/542 , C07K14/005 , C12N2770/16022
摘要： The present invention relates to a synthetic plant-optimized nucleic acid molecule having a Norwalk virus capsid protein coding nucleotide sequence, and nucleic acid constructs, host cells, expression systems, and plants having the plant-optimized Norwalk virus nucleic acid molecule. The present invention also relates to a method of producing Norwalk virus capsid protein virus-like particles in a transgenic plant or transgenic plant seed transformed with a plant-optimized nucleic acid molecule encoding Norwalk virus capsid protein. The plant or a component thereof can be administered to a subject under conditions effective to immunize the subject against disease resulting from infection by a Norovirus, including Norwalk virus. An oral vaccine for immunization of a subject against Norwalk virus infection is also disclosed.
摘要翻译：本发明涉及具有Norwalk病毒衣壳蛋白编码核苷酸序列的合成植物优化核酸分子，以及具有植物优化诺瓦克病毒核酸分子的核酸构建体，宿主细胞，表达系统和植物。本发明还涉及在用植物优化的编码诺瓦克病毒衣壳蛋白的核酸分子转化的转基因植物或转基因植物种子中产生诺瓦克病毒衣壳蛋白病毒样颗粒的方法。植物或其组分可以在有效免疫受试者的病症下施用于受诺如病毒（包括诺瓦克病毒）感染引起的疾病的病症。还公开了用于免疫Norwalk病毒感染的受试者的口服疫苗。

8. 发明申请

US20100254964A1 Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof 有权
标题翻译：改良的Bouganin蛋白，细胞毒素及其用途
公开(公告)号：US20100254964A1
公开(公告)日：2010-10-07
申请号：US12784820
申请日：2010-05-21
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61K38/47 , A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译：本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。

9. 发明授权

US07339031B2 Modified bouganin proteins, cytotoxins and methods and uses thereof 有权
标题翻译：改良的bouganin蛋白，细胞毒素及其方法和用途
公开(公告)号：US07339031B2
公开(公告)日：2008-03-04
申请号：US11084080
申请日：2005-03-18
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： C07K14/00 , C07K16/40 , C12P21/04
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译：本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。

10. 发明授权

US07754853B2 TNF alpha-binding polypeptide compositions and methods 失效
标题翻译： TNFα结合多肽组合物和方法
公开(公告)号：US07754853B2
公开(公告)日：2010-07-13
申请号：US11005726
申请日：2004-12-07
申请人： Koen Hellendoorn , Matthew Baker , Francis J. Carr
发明人： Koen Hellendoorn , Matthew Baker , Francis J. Carr
IPC分类号： A61K38/00
CPC分类号： C07K7/08 , C07K16/241 , C07K2317/24 , C07K2317/56
摘要： This invention pertains to a TNF alpha-binding polypeptide composition comprising at least one of a modified heavy chain variable region polypeptide or a modified light chain variable region polypeptide that is capable of specifically binding to human TNF alpha. The modified heavy and light chain variable region polypeptides of the TNF alpha binding polypeptide are modified by at least one amino acid residue substitution, deletion or addition and are homologous to the heavy and light chain variable regions, respectively, of a non-human monoclonal antibody that specifically binds human TNF alpha. The polypeptide compositions of the invention comprising modified heavy and light chain variable region polypeptides are less immunogenic in a human than are the homologous heavy and light chain variable region polypeptides from a non-human animal.
摘要翻译：本发明涉及包含能够特异性结合人TNFα的修饰的重链可变区多肽或修饰的轻链可变区多肽中的至少一种的TNFα结合多肽组合物。通过至少一个氨基酸残基取代，缺失或添加修饰TNFα结合多肽的修饰的重链和轻链可变区多肽，并分别与非人单克隆抗体的重链和轻链可变区同源其特异性结合人TNFα。包含修饰的重链和轻链可变区多肽的本发明的多肽组合物在人类中比来自非人动物的同源重链和轻链可变区多肽的免疫原性较低。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式